DOI: 10.12890/2026_007396
Ectopic ACTH syndrome presenting as refractory hypokalemia in metastatic castration-resistant prostate cancer with neuroendocrine transformation
Authors
jdelpaggio@nosm.ca
Keywords
Neuroendocrine neoplasm, ectopic ACTH syndrome, hypokalemia, prostate cancerAbstract
Ectopic adrenocorticotropic hormone (ACTH) syndrome resulting from neuroendocrine transformation of prostate adenocarcinoma may present with refractory hypokalemia as an initial manifestation. Because hypokalemia is often attributed to other more common aetiologies, the diagnosis is often overlooked, leading to delayed management. A 62-year-old man with metastatic castration-resistant prostate cancer (mCRPC) with neuroendocrine transformation presented with persistent hypokalemia. He later developed severe hypokalemia, metabolic alkalosis, and hypertension with disease progression. Endocrine workup revealed markedly elevated cortisol, no suppression on low dose dexamethasone testing, and elevated ACTH. Imaging showed no pituitary or adrenal lesions but demonstrated progression of metastatic disease. These findings supported ectopic ACTH secretion secondary to neuroendocrine transformation. Before initiation of the appropriate treatment, he developed supraventricular tachycardia, hypotension, pulmonary edema, and died. This case underscores the importance of considering paraneoplastic endocrine syndromes, such as ectopic ACTH secretion, in patients with malignancies and unexplained or refractory electrolyte disturbances—particularly in the context of neuroendocrine transformation.
References
- Unwin RJ, Luft FC, Shirley DG. Pathophysiology and management of hypokalemia: a clinical perspective. Nat Rev Nephrol. 2011;7(2):75-84. doi: 10.1038/nrneph.2010.175.
- Alexandraki KI, Grossman AB. The ectopic ACTH syndrome. Rev Endocr Metab Disord. 2010;11(2):117-26. doi: 10.1007/s11154-010-9139-z.
- Nyquist MD, Corella A, Coleman I, De Sarkar N, Kaipainen A, Ha G, et al. Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress. Cell Rep. 2020;31(8):107669. doi: 10.1016/j.celrep.2020.107669.
- Surintrspanont J, Zhou M. Prostate Pathology: What is New in the 2022 WHO Classification of Urinary and Male Genital Tumors? Pathologica. 2022;115(1):41-56. doi: 10.32074/1591-951X-822.
- Torpy DJ, Mullen N, Ilias I, Nieman LK. Association of hypertension and hypokalemia with Cushing’s syndrome caused by ectopic ACTH secretion: a series of 58 cases. Ann N Y Acad Sci. 2002;970:134-44. doi: 10.1111/j.1749-6632.2002.tb04419.x.
- Walker BR, Campbell JC, Fraser R, Stewart PM, Edwards CR. Mineralocorticoid excess and inhibition of 11 beta-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clin Endocrinol (Oxf). 1992;37(6):483-92. doi: 10.1111/j.1365-2265.1992.tb01478.x. PMID: 1337504.
- Arteaga E, Fardella C, Campusano C, Cárdenas I, Martinez P. Persistent hypokalemia after successful adrenalectomy in a patient with Cushing’s syndrome due to ectopic ACTH secretion: possible role of 11beta-hydroxysteroid dehydrogenase inhibition. J Endocrinol Invest. 1999;22(11):857-9. doi: 10.1007/BF03343659.
- Ragnarsson O, Juhlin CC, Torpy DJ, Falhammar H. A clinical perspective on ectopic Cushing’s syndrome. Trends Endocrinol Metab. 2024;35(4):347-360. doi: 10.1016/j.tem.2023.12.003.
- Elston MS, Crawford VB, Swarbrick M, Dray MS, Head M, Conaglen JV. Severe Cushing’s syndrome due to small cell prostate carcinoma: a case and review of literature. Endocr Connect. 2017;6(5):R80-R86. doi: 10.1530/EC-17-0081.
- Takeuchi M, Sato J, Manaka K, Tanaka M, Matsui H, Sato Y, et al. Molecular analysis and literature-based hypothesis of an immunonegative prostate small cell carcinoma causing ectopic ACTH syndrome. Endocr J. 2019;66(6):547-554. doi: 10.1507/endocrj.EJ18-0563.
